NYSE:LLYPharmaceuticals
Did Slower Foundayo Uptake and New Deals Just Recast Eli Lilly's (LLY) Obesity Playbook?
In recent days, Eli Lilly’s newly approved oral GLP-1 weight-loss drug Foundayo has shown slower-than-hoped prescription uptake, lagging Novo Nordisk’s oral Wegovy and raising questions about Lilly’s competitive position in the expanding obesity market.
At the same time, Lilly is reshaping its pipeline through moves such as exiting a RIPK1 collaboration with Rigel and agreeing to acquire Kelonia Therapeutics for about US$3.25 billion upfront to deepen its oncology and genetic medicines...